Angiotensin inhibitor vaccine - BTG

Drug Profile

Angiotensin inhibitor vaccine - BTG

Alternative Names: Angiotension Therapeutic Vaccine; Hypertension vaccine - BTG; PMD 3117

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protherics
  • Developer BTG
  • Class Antihypertensives; Heart failure therapies; Vaccines
  • Mechanism of Action Angiotensin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension in United Kingdom (IM, Injection)
  • 30 Nov 2009 Phase-I clinical trials in Hypertension in United Kingdom (IM)
  • 05 Nov 2009 Preclinical trials are ongoing in the UK in preparation for a phase I trial to test different doses of adjuvant
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top